Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities
Dr. Anatoly Dritschilo remains Chairman of the Board and Co-CEO overseeing scientific and clinical trial activities
GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ('Shuttle Pharma' or the 'Company'), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of Christopher Cooper as interim Co-Chief Executive Officer focused on enhancing the Company's capital markets and business capabilities. Dr. Anatoly Dritschilo, Chairman of the Company's Board of Directors, will continue in his role as Co-CEO overseeing the Company's scientific and clinical trial activities.
'I am excited to welcome Christopher Cooper as Co-CEO of Shuttle Pharma,' commented Dr. Anatoly Dritschilo, Chairman of the Board and CEO of Shuttle Pharma. 'Christopher brings a wealth of business acumen which when balanced with the inherent scientific expertise of the entire Shuttle Pharma team should allow for a highly effective executive structure that should inspire confidence going forward. I believe this appointment will enhance decision-making, supports fundraising, and prepares us for the accelerated achievement of key milestones in the future.'
Christopher Cooper added, 'I am enthusiastic to join the incredibly talented team at Shuttle Pharma as we aim to improve the lives of millions impacted by cancer and bring hope to patients and families around the world. The Co-CEO structure will allow for parallel execution of R&D, regulatory and general business operations. I look forward to leveraging my business experience to allow Dr. Dritschilo to focus more of his efforts going forward on the successful execution of the Company's ongoing key Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma and continued advancement of the Diagnostics subsidiary.'
Mr. Cooper has more than 27 years of experience in management and finance, having worked in the oil and gas, telecommunications and technology industries. In addition to his appointment as Interim Co-CEO of the Shuttle Pharma, Mr. Cooper also serves as President, CEO and Founder of First Towers & Fiber Corp., a telecommunications infrastructure company with operations in Latin America, positions he has held since 2017. From 2010 until 2017, Mr. Cooper served as President and CEO of Aroway Energy, Inc., a Vancouver, British Columbia-based oil and gas company, where he was responsible for overseeing day to day operations, financial reporting, and oversaw acquisitions and debt and equity financing. From 1998 until 2010, Mr. Cooper served as a Corporate Consultant to various companies in the technology and resources sectors, oversaw restricting activities for several distressed public companies, and was responsible for raising more than $100 million in debt and equity for his clients. Mr. Cooper received his MBA from Dowling College in 1995 and his BBA in Business Administration from Hofstra University.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include, but are not limited to, statements concerning the development of our company. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the 'Risk Factors' section of Shuttle Pharma's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 24, 2025, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Shuttle PharmaceuticalsAnatoly Dritschilo, M.D., Co-CEO240-403-4212info@shuttlepharma.com
Investor ContactsLytham Partners, LLCRobert Blum602-889-9700shph@lythampartners.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
JSW Steel's crude steel production rises 8% YoY to 22.73 lakh tonnes in May 2025
By Aman Shukla Published on June 9, 2025, 10:45 IST JSW Steel reported its consolidated crude steel production for May 2025 at 22.73 lakh tonnes, reflecting an 8% year-on-year increase compared to 20.98 lakh tonnes in May 2024. The company's cumulative crude steel production for FY26 up to May stood at 47.56 lakh tonnes, marking a 13% rise from 42.18 lakh tonnes recorded in the corresponding period of the previous financial year. Within the overall figures, Indian operations contributed 21.94 lakh tonnes in May 2025, up from 20.13 lakh tonnes a year ago, representing a 9% growth. Cumulative production from Indian operations reached 45.93 lakh tonnes in the current fiscal, compared to 40.68 lakh tonnes last year, also indicating a 13% increase. JSW Steel's US-based Ohio facility produced 0.79 lakh tonnes during the month, slightly lower than the 0.85 lakh tonnes produced in May 2024. Year-to-date output from this unit reached 1.63 lakh tonnes, up from 1.50 lakh tonnes over the same period last year. The company reported 80% capacity utilisation for its Indian operations in May 2025, affected by a planned maintenance shutdown at the Dolvi plant's blast furnace. Operations resumed at the furnace on May 30, 2025. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
an hour ago
- Yahoo
Doctor speaks out about conditions at two Fraser Health emergency rooms
An emergency physician is blowing the whistle on deteriorating conditions in two emergency rooms in the Fraser Health authority alleging her job was threatened after she warned patient conditions in the ER had become dangerous. CBC News has obtained a copy of a lawsuit she's filed. As Michelle Ghoussoub reportS, it describes a culture of silence in an overburdened system.
Yahoo
2 hours ago
- Yahoo
Quantum Computing Inc. Reports First Quarter 2025 Financial Results
HOBOKEN, N.J., May 15, 2025 /PRNewswire/ -- Quantum Computing Inc. ("QCi" or the "Company") (Nasdaq: QUBT), an innovative, integrated photonics and quantum optics technology company, today released financial results for the three-month period ended March 31, 2025. Dr. Yuping Huang, Interim Chief Executive Officer of QCi, commented, "QCi delivered solid operational and financial progress in the first quarter, strengthening our balance sheet and advancing key strategic initiatives. We completed construction during the quarter of our Quantum Photonic Chip Foundry in Tempe, Arizona, a major milestone that positions us to meet growing demand for thin film lithium niobate (TFLN) photonic chips, underscored by the announcement of a fifth purchase during the period. We're encouraged by our early traction, which is the first step in what we believe is a significant, multi-year opportunity to serve the expanding markets in datacom, telecom, and quantum-enabled applications. In parallel, we continued to deepen engagement with both government and commercial partners, reinforcing the growing interest in our quantum and photonic machines and positioning QCi to capitalize on emerging opportunities ahead." First Quarter 2025 Financial Highlights First quarter 2025 revenues totaled approximately $39,000 (33% gross margin) compared to $27,000 (41% gross margin) generated in the first quarter of 2024. Gross margin can vary at our current revenue levels. As such, the year-over-year decrease is not unexpected. First quarter 2025 operating expenses totaled $8.3 million compared to the previous year's first quarter operating expenses of $6.3 million. The year-over-year increase was primarily driven by higher employee-based expenses. The Company reported net income attributable to common stockholders of $17.0 million, or $0.13 per basic share for the first quarter of 2025, compared to a net loss attributable to common stockholders of $6.4 million or $(0.08) per basic share for the same period of the previous year. The increase in net income this quarter was primarily due to a $23.6 million non-cash gain on the mark-to-market valuation of the Company's warrant liability as a result of our merger with QPhoton in June 2022. Total assets at March 31, 2025 were $242.5 million, increasing from $153.6 million at December 31, 2024. Cash and cash equivalents at March 31, 2025 increased by $87.5 million to $166.4 million from year-end 2024. During the first quarter, the Company raised total net proceeds of $93.6 million through a private placement offering of common stock. Total liabilities at March 31, 2025 were $21.7 million, a decrease of $24.6 million compared to year-end 2024, driven primarily by the previously-mentioned non-cash changes in the fair value of the Company's warrant liability. As of March 31, 2025, the Company had shareholders' equity totaling $220.8 million. First Quarter 2025 Operational Highlights Quantum Photonic Chip Foundry Update: During the quarter, QCi completed construction of its Quantum Photonic Chip Foundry in Tempe, Arizona, achieving a key milestone in scaling its U.S.-based TFLN manufacturing services. The Company is now establishing its process design kit (PDK) and filling customer orders. To date, the Company has received five initial orders for its foundry services. Advancing Quantum Machine Adoption: On January 15, 2025, QCi announced a collaboration with Sanders Tri-Institutional Therapeutics Discovery Institute (Sanders TDI), a non-profit drug discovery institute comprising Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Cornell Medicine. Through this partnership, Sanders TDI will leverage cloud-based access to QCi's Dirac-3 quantum optimization machine to support computational chemistry and biomolecular modeling research. This collaboration highlights growing adoption of QCi's quantum systems in real-world biomedical applications. Board Appointment Strengthens Strategic Leadership: On March 26, 2025, QCi appointed Eric Schwartz to its Board of Directors. Mr. Schwartz brings over 20 years of experience in corporate finance, mergers and acquisitions, and corporate strategy, with a strong track record guiding companies through commercialization and manufacturing scale-up. His expertise will support QCi's growth initiatives as the Company advances its TFLN chip foundry and drives market adoption of its quantum machines. Strengthening Sales & Market Presence: The Company continued to expand its commercial and government engagement, participating in numerous trade shows and conferences during the quarter to showcase its quantum optimization and photonic chip solutions to prospective customers and partners. Advancing Strategic Partnerships with NASA: Subsequent to the quarter on April 30, 2025, QCi was awarded a subcontract valued at approximately $406,000 through Analytical Mechanics Associates (AMA) to support NASA's Langley Research Center. Under the project, QCi will use its Dirac-3 quantum computer to develop a quantum-based technique for removing sunlight noise from space-based LIDAR data, an obstacle that has historically limited NASA's ability to conduct reliable daytime Earth observation. This project builds on QCi's prior work with NASA. Expanding Commercial Adoption of Quantum Solutions: Subsequent to the quarter, QCi secured two additional customer orders, reflecting growing global demand for its quantum machines. On April 1, 2025, the Company announced the sale of a Quantum Photonic Vibrometer to the Department of Aerospace Structures and Materials at Delft University of Technology in the Netherlands, supporting advanced research in non-destructive testing and structural health monitoring. Later in the month, on April 22, 2025, QCi announced the sale of an EmuCore reservoir computing device to a major automotive manufacturer for research and development use. These orders underscore QCi's strategy to broaden awareness and adoption of its quantum solutions across both academic and industrial markets globally. Earnings Conference Call The Company will host its first quarter conference call on Thursday, May 15, 2025, at 4:30 p.m. To access the live webcast of the conference call, visit the QCi Investor Relations page at Investors may also access the webcast via the following link: To participate in the call by phone, dial (888) 506-0062 approximately five minutes prior to the scheduled start time. International callers please dial (973) 528-0011. Callers should use access code: 832763. A replay of the teleconference will be available until May 22, 2025, and may be accessed by dialing (877) 481-4010. International callers may dial (919) 882-2331. Callers should use conference ID: 52325. About Quantum Computing Inc. Quantum Computing Inc. (Nasdaq: QUBT) is an innovative, integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines to the world today. QCi's products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer unique capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications. Company Contact:Rosalyn Christian/John NesbettIMS Investor Relationsinvestors@ Forward-Looking Statements This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, generally identified by terms such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," "aim to," or variations of these or similar words, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of QCi and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including the timing of orders and revenue, and the outcome of ongoing collaborations and demonstration projects with certain U.S. government agencies, academic institutions and commercial customers, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, QCi undertakes no obligation to update or revise forward-looking statements to reflect changed conditions. IMPORTANT NOTICE TO USERS (summary only, click here for full text of notice): All information is unaudited unless otherwise noted or accompanied by an audit opinion and is subject to the more comprehensive information contained in our SEC reports and filings. We do not endorse third-party information. All information speaks as of the last fiscal quarter or year for which we have filed a Form 10-K or 10-Q, or for historical information the date or period expressly indicated in or with such information. We undertake no duty to update the information. Forward-looking statements are subject to risks and uncertainties described in our Forms 10-Q and 10-K. QUANTUM COMPUTING INC. Consolidated Balance Sheets (in thousands, except par value data)March 31, December 31,2025 2024Assets Current assets: Cash and cash equivalents$ 166,429 $ 78,945 Accounts receivable, net 2027 Inventory 13118 Prepaid expenses and other current assets 660161Total current assets 167,24079,151Property and equipment, net 9,9768,212Operating lease right-of-use assets 1,4191,522Intangible assets, net 8,1968,972Goodwill 55,57355,573Other non-current assets 129129Total assets$ 242,533 $ 153,559 Liabilities and Stockholders' Equity Current liabilities: Accounts payable$ 2,022 $ 1,372 Accrued expenses 6472,134 Deferred revenue 8379 Other current liabilities 990974Total current liabilities 3,7424,559Derivative liability 16,90240,532Operating lease liabilities 1,0621,181Total liabilities 21,70646,272Stockholders' equity: Common stock, $0.0001 par value, 250,000 thousand shares authorized; 137,322 thousand and 129,012 thousand shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively 1413 Additional paid-in capital 404,313307,756 Accumulated deficit (183,500)(200,482)Total stockholders' equity 220,827107,287Total liabilities and stockholders' equity$ 242,533 $ 153,559 QUANTUM COMPUTING INC. Consolidated Statements of Operations (in thousands, except per share data)Three Months EndedMarch 31,2025 2024Total revenue$ 39 $ 27Cost of revenue 2616Gross profit 1311Operating expenses Research and development 2,9852,220Sales and marketing 672451General and administrative 4,6423,659Total operating expenses 8,2996,330Loss from operations (8,286)(6,319)Non-operating income (expense) Interest and other income 1,69638Interest expense, net (58)(155)Change in fair value of warrant liabilities 23,630-Income (loss) before income tax provision 16,982(6,436)Income tax provision --Net income (loss) 16,982(6,436) Net income (loss) attributable to common stockholders$ 16,982 $ (6,436) Earnings (loss) per share: Basic$ 0.13 $ (0.08)Diluted$ 0.11 $ (0.08)Weighted average shares used in computing net earnings (loss) per common share: Basic 135,21781,934Diluted 153,00681,934 View original content to download multimedia: SOURCE Quantum Computing Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
